GlassScriptPhysician profile
Randy R Shemer
NPI 1376567610
$6,655.73
in general payments reported to CMS, 2019-2025
38 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,375 · 2020: $2,024 · 2021: $534 · 2022: $291 · 2023: $95.03 · 2024: $45.30 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $781.54 | 2019-2022 | |
| Novo Nordisk INC | $548.74 | 2019-2025 | Ozempic, Wegovy |
| Pfizer INC. | $529.14 | 2019-2023 | |
| Abbvie INC. | $458.85 | 2019-2025 | Botox |
| Allergan, INC. | $420.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $419.87 | 2019-2020 | |
| Amarin Pharma, INC. | $396.28 | 2019-2021 | |
| Lilly USA, LLC | $377.55 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $351.01 | 2019-2022 | |
| Amgen INC. | $344.04 | 2019-2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $321.73 | 2019-2022 | |
| Horizon Therapeutics Plc | $284.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $209.99 | 2019-2022 | |
| Astellas Pharma US INC | $91.18 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Shemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.